Skip to main content

Table 5 Total number of events within 365 days follow-up in a cohort of patients acutely hospitalized with asthma (n = 1023), stratified by suPAR quartiles and blood eosinophil count

From: The biomarkers suPAR and blood eosinophils are associated with hospital readmissions and mortality in asthma – a retrospective cohort study

 

suPAR

Blood Eosinophils

1st Quartile

2nd Quartile

3rd Quartile

4th Quartile

Low (N)*

109

104

92

147

 No event, N (%)

61 (56.0)

42 (40.4)

51 (55.4)

50 (34.0)

 Readmitted†, N (%)

47 (43.1)

59 (56.7)

35 (38.0)

66 (44.9)

 Mortality, N (%)

1 (0.9)

3 (2.9)

6 (6.5)

31 (21.1)

Intermediate (N)*

67

52

60

58

 No event, N (%)

40 (59.7)

30 (57.7)

25 (41.7)

21 (36.2)

 Readmitted†, N (%)

27 (40.3)

21 (40.4)

33 (55.0)

32 (55.2)

 Mortality, N (%)

0 (0)

1 (1.9)

2 (3.3)

5 (8.6)

High (N)*

101

98

68

67

 No event, N (%)

70 (69.3)

72 (73.5)

36 (52.9)

30 (44.8)

 Readmitted†, N (%)

30 (29.7)

26 (26.5)

31 (45.6)

34 (50.7)

 Mortality, N (%)

1 (0.9)

0 (0)

1 (1.5)

3 (4.5)

  1. *This analysis only included patients with full 365 days follow-up and blood eosinophil results available (n = 1023)
  2. †Only including readmission events in patients without consequent death in the duration of the follow-up period
  3. suPAR quartile cut-offs: Q1: < 1.9 ng/mL (n = 282), Q2: 1.9–2.6 ng/mL (n = 266), Q3: 2.61–3.5 ng/mL (n = 237), Q4: > 3.5 ng/mL (n = 283)
  4. Blood eosinophil count cut-offs defined as Low (< 150 cells/μL, n = 452), Medium (150–300 cells/μL, n = 237), and High (> 300 cells/μL, n = 334)
  5. suPAR – Soluble urokinase plasminogen activator receptor
Back to article page